Abstract Title:

[The double-blind randomized placebo-controlled trial of N-acetylcysteine use in schizophrenia: preliminary results].

Abstract Source:

Zh Nevrol Psikhiatr Im S S Korsakova. 2020 ;120(9):66-71. PMID: 33081449

Abstract Author(s):

A S Pyatoykina, T V Zhilyaeva, I V Semennov, G A Mishanov, A S Blagonravova, G E Mazo

Article Affiliation:

A S Pyatoykina


BACKGROUND: Currently, oxidative stress as part of the pathogenesis of schizophrenia attracts much attention. In this regard, it becomes relevant to assess the level of redox imbalance in patients with schizophrenia, its impact on existing symptoms and the possibility of its treatment. The antioxidant N-acetylcysteine is one of the potential drugs that affects oxidative stress.

OBJECTIVE: To study the possibilities of the use of N-acetylcysteine in patients with schizophrenia.

MATERIAL AND METHODS: The study included 20 patients diagnosed with paranoid schizophrenia with the disease duration of less than 3 years, randomly assigned to the main group (taking N-acetylcysteine at a dose of 2000 mg per day for 60 days) and a comparison group (placebo) in a double-blinded manner. At the beginning and end of the study, cognitive functions were evaluated using the specialized instrument BACS, the severity of psychopathological symptoms was evaluated using PANSS, and blood was collected to determine the level of glutathione (GSH), which is a metabolite of N-acetylcysteine.

RESULTS: There was a significant decrease in positive PANSS score (=0.013), negative PANSS score (=0.002) and the general pathology PANSS score (=0.004) in the main group. Compared with the comparison group, the dynamics of the negative PANSS score (=0.005) and the general psychopathology PANSS score (=0.004) was significantly different. When assessing the dynamics of cognitive functions in the main group, a significant improvement in indicators was established in the task for a sequence of numbers that characterizes working memory (=0.037). The level of GSH significantly increased in the main group (=0.01), however, there were no statistically significant differences between groups at the final visit.

CONCLUSION: N-acetylcysteine has a positive effect on the negative, general psychopathology PANSS scores, some cognitive functions, in particular, working memory, that allows considering this drug as a promising method of augmentation of schizophrenia therapy and requires further attentive study.

Study Type : Human Study

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.